Spots Global Cancer Trial Database for recurrent b acute lymphoblastic leukemia

Every month we try and update this database with for recurrent b acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies	NCT05418088	Recurrent Acute... Recurrent B Acu... Recurrent B-Cel... Recurrent Chron... Recurrent High ... Recurrent Indol... Recurrent Non-H... Recurrent Trans... Refractory Acut... Refractory B Ac... Refractory B-Ce... Refractory Chro... Refractory High... Refractory Indo... Refractory Non-... Refractory Tran...	Anti-CD19/CD20/... Cyclophosphamid... Fludarabine Pho...	18 Years -	Ohio State University Comprehensive Cancer Center
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia	NCT02981628	Recurrent B Acu... Recurrent B Lym... Refractory B Ac... Refractory B Ly...	Asparaginase Er... Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cyclophosphamid... Cytarabine Diagnostic Imag... Inotuzumab Ozog... Leucovorin Calc... Lumbar Puncture Methotrexate Pegaspargase Vincristine	1 Year - 21 Years	Children's Oncology Group
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	NCT02101853	Recurrent B Acu...	Allogeneic Hema... Asparaginase Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Leucovorin Calc... Mercaptopurine Methotrexate Mitoxantrone Mitoxantrone Hy... Pegaspargase Pharmacological... Radiation Thera... Therapeutic Hyd... Thioguanine Vincristine Vincristine Sul...	1 Year - 31 Years	National Cancer Institute (NCI)
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	NCT05032183	Recurrent Adult... Recurrent B Acu... Recurrent T Acu... Refractory B Ac... Refractory Lymp... Refractory T Ac...	Cyclophosphamid... Cytarabine Dexamethasone Filgrastim-sndz Leucovorin Mercaptopurine Mesna Methotrexate Pegfilgrastim Prednisone Rituximab Tagraxofusp-erz... Vincristine	18 Years - 70 Years	M.D. Anderson Cancer Center
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	NCT04872790	B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed...	Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col...	18 Years -	OHSU Knight Cancer Institute
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	NCT04681105	Recurrent Acute... Recurrent B Acu... Recurrent Blast... Recurrent Chron... Recurrent Hairy... Recurrent Hemat... Recurrent Hodgk... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Blas... Refractory Chro... Refractory Hair... Refractory Hema... Refractory Hodg... Refractory T Ac... Systemic Mastoc...	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	12 Years -	City of Hope Medical Center
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat	NCT05320380	Recurrent Acute... Recurrent B Acu... Recurrent Mixed... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Mixe... Refractory T Ac...	Anti-CD123 ADC ... Bone Marrow Asp... Cytarabine Fludarabine Pho... Hydrocortisone ... Liposome-encaps... Methotrexate Prednisolone	12 Months - 22 Years	Children's Oncology Group
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia	NCT03698552	Blasts 5 Percen... CD22 Positive Philadelphia Ch... Recurrent B Acu... Refractory B Ac...	ADCT-602	18 Years -	M.D. Anderson Cancer Center
CD19-Specific T Cells Post AlloSCT	NCT03579888	B Acute Lymphob... Recurrent B Acu... Recurrent Chron... Recurrent Diffu... Recurrent Mantl... Recurrent Non-H... Recurrent Ph-Li... Recurrent Prima... Recurrent Small... Refractory B Ac... Refractory Chro... Refractory Diff... Refractory Mant... Refractory Non-... Refractory Ph-L... Refractory Prim... Refractory Smal...	Autologous CD19... Cyclophosphamid... Fludarabine	18 Years - 70 Years	M.D. Anderson Cancer Center
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease	NCT03441061	Acute Lymphobla... B Acute Lymphob... Recurrent B Acu...	Inotuzumab Ozog...	18 Years -	M.D. Anderson Cancer Center
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	NCT02101853	Recurrent B Acu...	Allogeneic Hema... Asparaginase Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Leucovorin Calc... Mercaptopurine Methotrexate Mitoxantrone Mitoxantrone Hy... Pegaspargase Pharmacological... Radiation Thera... Therapeutic Hyd... Thioguanine Vincristine Vincristine Sul...	1 Year - 31 Years	National Cancer Institute (NCI)
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)	NCT04546399	Down Syndrome Recurrent B Acu...	3-Dimensional C... Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Hydrocortisone ... Leucovorin Calc... Mercaptopurine Methotrexate Nivolumab Pegaspargase Thioguanine Vincristine Sul...	1 Year - 30 Years	National Cancer Institute (NCI)
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia	NCT03518112	Philadelphia Ch... Recurrent B Acu... Refractory B Ac...	Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Filgrastim Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegfilgrastim Rituximab Vincristine Sul...	18 Years -	M.D. Anderson Cancer Center
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat	NCT05320380	Recurrent Acute... Recurrent B Acu... Recurrent Mixed... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Mixe... Refractory T Ac...	Anti-CD123 ADC ... Bone Marrow Asp... Cytarabine Fludarabine Pho... Hydrocortisone ... Liposome-encaps... Methotrexate Prednisolone	12 Months - 22 Years	Children's Oncology Group
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia	NCT02420717	Recurrent B Acu... Recurrent Ph-Li... Refractory B Ac... Refractory Ph-L...	Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Laboratory Biom... Leucovorin Mercaptopurine Methotrexate Prednisone Rituximab Ruxolitinib Pho... Vincristine	10 Years -	M.D. Anderson Cancer Center
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	NCT04872790	B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed...	Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col...	18 Years -	OHSU Knight Cancer Institute
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia	NCT03518112	Philadelphia Ch... Recurrent B Acu... Refractory B Ac...	Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Filgrastim Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegfilgrastim Rituximab Vincristine Sul...	18 Years -	M.D. Anderson Cancer Center
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia	NCT03472573	Recurrent B Acu... Refractory B Ac...	Palbociclib Dexamethasone	18 Years -	Thomas Jefferson University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: